370 related articles for article (PubMed ID: 12057039)
21. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
Emlet DR; Brown KA; Kociban DL; Pollice AA; Smith CA; Ong BB; Shackney SE
Mol Cancer Ther; 2007 Oct; 6(10):2664-74. PubMed ID: 17938260
[TBL] [Abstract][Full Text] [Related]
22. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Sledge GW
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Fuino L; Bali P; Wittmann S; Donapaty S; Guo F; Yamaguchi H; Wang HG; Atadja P; Bhalla K
Mol Cancer Ther; 2003 Oct; 2(10):971-84. PubMed ID: 14578462
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of gemcitabine in lung cancer: part I.
Bunn PA
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-1. PubMed ID: 9194472
[No Abstract] [Full Text] [Related]
26. Trastuzumab in the treatment of non-small cell lung cancer.
Azzoli CG; Krug LM; Miller VA; Kris MG; Mass R
Semin Oncol; 2002 Feb; 29(1 Suppl 4):59-65. PubMed ID: 11894015
[TBL] [Abstract][Full Text] [Related]
27. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
Yardley DA; Burris HA; Hanson S; Greco FA; Spigel DR; Barton J; Hainsworth JD
Clin Breast Cancer; 2009 Aug; 9(3):178-83. PubMed ID: 19661042
[TBL] [Abstract][Full Text] [Related]
28. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
Seoane S; Montero JC; Ocaña A; Pandiella A
J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
[TBL] [Abstract][Full Text] [Related]
29. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
30. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
Kan S; Koido S; Okamoto M; Hayashi K; Ito M; Kamata Y; Komita H; Ishidao T; Nagasaki E; Homma S
Oncol Rep; 2015 Jul; 34(1):504-10. PubMed ID: 25976081
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K; Bellone S; Cocco E; Cargnelutti M; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2010 Jan; 102(1):134-43. PubMed ID: 19920829
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
35. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
36. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
37. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
38. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
[TBL] [Abstract][Full Text] [Related]
39. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
40. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
Ohashi K; Hotta K; Hirata T; Aoe K; Kozuki T; Ninomiya K; Kayatani H; Yanai H; Toyooka S; Hinotsu S; Takata M; Kiura K
Clin Lung Cancer; 2017 Jan; 18(1):92-95. PubMed ID: 27497829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]